Compare · BCDA vs MRNA
BCDA vs MRNA
Side-by-side comparison of BioCardia Inc. (BCDA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCDA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 3706.7x BCDA ($17.1M).
- Over the past year, BCDA is down 44.6% and MRNA is up 502.6% - MRNA leads by 547.2 points.
- MRNA has been more active in the news (11 items in the past 4 weeks vs 9 for BCDA).
- MRNA has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- BioCardia Inc.
- Moderna Inc.
- Price
- $1.07+7.50%
- $149.09-6.12%
- Market cap
- $17.1M
- $63.41B
- 1M return
- +32.70%
- +167.14%
- 1Y return
- -44.59%
- +502.63%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 11
- Recent ratings
- 1
- 25
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BCDA
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
- BioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- President and CEO Altman Peter bought $5,022 worth of shares (5,400 units at $0.93), increasing direct ownership by 1% to 381,115 units (SEC Form 4)
- President and CEO Altman Peter bought $1,748 worth of shares (1,900 units at $0.92), increasing direct ownership by 0.51% to 375,785 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by BioCardia Inc.
- BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
- BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
- President and CEO Altman Peter bought $3,900 worth of shares (5,000 units at $0.78), increasing direct ownership by 1% to 373,885 units (SEC Form 4)
Latest MRNA
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.